Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Hympavzi Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Hympavzi (marstacimab-hncq) Coverage Criteria

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Hympavzi used for routine prophylaxis to prevent or reduce bleeding episodes in members aged 6 years and older with hemophilia A or hemophilia B under UnitedHealthcare commercial pharmacy coverage.

    Policy Summary
    PayerUnitedHealthcare
    PolicyHympavzi (marstacimab-hncq) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming hemophilia A or B, age 6 years or older, and routine prophylaxis use.
    SourceLink
    POLICY UPDATE CHANGES

    The policy expanded coverage criteria to include hemophilia A with or without factor VIII inhibitors and hemophilia B with or without factor IX inhibitors.

    The policy updated the minimum age requirement to patients 6 years of age and older.

    The indications were updated to include prevention or reduction in the frequency of bleeding episodes.

    6+ yearsMinimum patient age for initial authorization
    12 monthsInitial authorization duration
    12 monthsReauthorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Hemophilia indications covered
    With or without inhibitorsFactor inhibitor status permitted

    Coverage Criteria

    Hemophilia A Initial Authorization

    Covered when all of the following are met:

    Hemophilia A initial authorization

    • Diagnosis of hemophilia A.
    • Age: Patient is 6 years of age or older.>= 6 years
    • Treatment purpose: Prescribed for the prevention or reduction in frequency of bleeding episodes (i.e., routine prophylaxis).

    Hemophilia A Reauthorization

    Covered for reauthorization when the following is met:

    Positive clinical response: Documentation of positive clinical response to Hympavzi therapy.

    Authorization is issued for 12 months.

    Hemophilia B Initial Authorization

    Covered when all of the following are met:

    Hemophilia B initial authorization

    • Diagnosis of hemophilia B.
    • Age: Patient is 6 years of age or older.>= 6 years
    • Treatment purpose: Prescribed for the prevention or reduction in frequency of bleeding episodes (i.e., routine prophylaxis).

    Hemophilia B Reauthorization

    Covered for reauthorization when the following is met:

    Positive clinical response: Documentation of positive clinical response to Hympavzi therapy.

    Authorization is issued for 12 months.

    Initial Therapy Criteria

    Hemophilia A Initial Therapy

    Initial therapy for hemophilia A is covered when all criteria are met:

    Hemophilia A initial therapy

    • Diagnosis of hemophilia A.
    • Age: Patient is 6 years of age or older.>= 6 years
    • Treatment purpose: Hympavzi is prescribed for the prevention or reduction in frequency of bleeding episodes (i.e., routine prophylaxis).

    Hemophilia B Initial Therapy

    Initial therapy for hemophilia B is covered when all criteria are met:

    Continuation Therapy Criteria

    Hympavzi Continuation Therapy

    Reauthorization is covered when the following criterion is met:

    Positive clinical response: Documentation of positive clinical response to Hympavzi therapy.

    Authorization is issued for 12 months.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Hympavzi. Initial approval is available when all listed diagnosis, age, and prophylaxis criteria are met.

    • Diagnosis of hemophilia A or hemophilia B.
    • Patient is 6 years of age or older.
    • Hympavzi is prescribed for the prevention or reduction in frequency of bleeding episodes (routine prophylaxis).
    Prior Authorization

    Authorization Period

    When approved, authorization for Hympavzi is issued for 12 months initially. Reauthorization is also issued for 12 months when the continuation requirement is met.

    • Initial authorization period: 12 months.
    • Reauthorization period: 12 months.

    Therapy Background

    Hympavzi (marstacimab-hncq) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 6 years of age and older with hemophilia A or hemophilia B. The indication includes patients with or without the relevant factor inhibitor: factor VIII inhibitors in hemophilia A and factor IX inhibitors in hemophilia B.

    Key Definitions

    Hemophilia A
    DefinitionA congenital deficiency of factor VIII.
    Factor VIII inhibitor statusMay occur with or without factor VIII inhibitors.
    Hemophilia B
    DefinitionA congenital deficiency of factor IX.
    Factor IX inhibitor statusMay occur with or without factor IX inhibitors.
    Routine prophylaxis
    PurposePrevention or reduction in the frequency of bleeding episodes.
    Policy Summary
    PayerUnitedHealthcare
    PolicyHympavzi (marstacimab-hncq) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming hemophilia A or B, age 6 years or older, and routine prophylaxis use.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaAuthorization and Documentation RequirementsTherapy BackgroundKey Definitions

    Hemophilia B initial therapy

    • Diagnosis of hemophilia B.
    • Age: Patient is 6 years of age or older.>= 6 years
    • Treatment purpose: Hympavzi is prescribed for the prevention or reduction in frequency of bleeding episodes (i.e., routine prophylaxis).
    Documentation Required

    Initial Authorization Documentation

    Submit documentation supporting the initial authorization request and confirming that all required criteria are met.

    • Document a diagnosis of hemophilia A or hemophilia B.
    • Document that the patient is at least 6 years of age.
    • Document that Hympavzi is prescribed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, document that the patient has experienced a positive clinical response to Hympavzi therapy.

    • Submit documentation of positive clinical response to ongoing Hympavzi therapy.
    Denial Risk

    Failure to Meet Initial Criteria

    Initial authorization may be denied when the request does not satisfy all required approval criteria.

    • No documented diagnosis of hemophilia A or hemophilia B.
    • Patient is younger than 6 years of age.
    • Hympavzi is not prescribed for prevention or reduction in frequency of bleeding episodes (routine prophylaxis).
    Denial Risk

    Insufficient Response Documentation

    Reauthorization may be denied when documentation does not establish a positive clinical response to Hympavzi therapy.

    • Positive clinical response to therapy is not documented.
    Clinical useRoutine prophylaxis.